A phase 2, multi-center, open label study evaluating clinical efficacy, safety, and pharmacodynamic effects of quarfloxacin (CX-3543) in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia (B-CLL)

Trial Profile

A phase 2, multi-center, open label study evaluating clinical efficacy, safety, and pharmacodynamic effects of quarfloxacin (CX-3543) in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia (B-CLL)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2008

At a glance

  • Drugs Quarfloxin (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Nov 2008 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Nov 2007 Trial centre added.
    • 08 Nov 2007 New trial centres added.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top